Title:
がん治療用予測因子
Document Type and Number:
Japanese Patent JP2014524571
Kind Code:
A
Abstract:
The present invention provides methods of predicting a response to a cancer treatment by determining CD68 level or PSMB1 (P11A) polymorphism in a biological sample and the presence or quantity of a second biomarker in the patient. The invention also provides kits and methods for treating cancer.
Inventors:
Richness, Deborah
Li, Wei Min
ヘニツ, Erin, デヴァイ
Li, Wei Min
ヘニツ, Erin, デヴァイ
Application Number:
JP2014525107A
Publication Date:
September 22, 2014
Filing Date:
August 08, 2012
Export Citation:
Assignee:
The JANSSEN PHARMACEUTICAL shoe ティカ N. Bex.
International Classes:
G01N33/574; A61K31/198; A61K31/573; A61K38/00; A61K39/395; A61K45/00; A61P35/02
Domestic Patent References:
| JP2006517093A | 2006-07-20 | |||
| JP2006517093A | 2006-07-20 |
Foreign References:
| US20090181393A1 | 2009-07-16 | |||
| US20090181393A1 | 2009-07-16 |
Other References:
JPN5014009659; ＣＨＲＩＳＴＩＡＮ ＳＴＥＩＤＬ ｅｔ ａｌ．: 'Ｔｕｍｏｒ-Ａｓｓｏｃｉａｔｅｄ Ｍａｃｒｏｐｈａｇｅｓ ａｎｄ Ｓｕｒｖｉｖａｌ ｉｎ Ｃｌａｓｓｉｃ Ｈｏｄｇｋｉｎ'ｓ Ｌｙｍｐｈｏｍａ' ＮＥＷ ＥＮＧＬＡＮＤ ＪＯＵＲＮＡＬ ＯＦ ＭＥＤＩＣＩＮＥ Ｖｏｌ．３６２，Ｎｏ．１０, 20100311, Ｐ．８７５-８８５
JPN5014009666; Ｌｉ Ｄｉｎｇ ｅｔ ａｌ．: 'Ｂｏｒｔｅｚｏｍｉｂ ｉｎ ｃｏｍｂｉｎａｔｉｏｎ ｗｉｔｈ ＩＧＥＶ ｃｈｅｍｏｔｈｅｒａｐｙ ｒｅｇｉｍｅｎ ｆｏｒ ａ ｐｒｉｍａｒｙ ｒｅｆｒａｃｔｏｒｙ Ｈｏｄｇｋｉｎ'ｓ ｌｙｍｐｈｏｍａ' ＬＥＵＫＥＭＩＡ ＲＥＳＥＡＲＣＨ Ｖｏｌ．３３，Ｎｏ．９, 20090901, Ｐ．ｅ１７０-ｅ１７２
JPN5014009658; ＭＩＮＮＡ ＴＡＳＫＩＮＥＮ: ＣＬＩＮＩＣＡＬ ＣＡＮＣＥＲ ＲＥＳＥＡＲＣＨ Ｖ１３ Ｎ１９, 20071001, Ｐ５７８４-５７８９
JPN5014009662; ＤＡＮＩＥＬＬＥ ＣＡＮＩＯＮＩ: ＪＯＵＲＮＡＬ ＯＦ ＣＬＩＮＩＣＡＬ ＯＮＣＯＬＯＧＹ Ｖ２６ Ｎ３, 20080120, Ｐ４４０-４４６
JPN6016004582; Ｆｒｉｅｄｂｅｒｇ ＪＷ ｅｔ ａｌ．: 'Ｔｈｅ ｃｏｍｂｉｎａｔｉｏｎ ｏｆ ｂｅｎｄａｍｕｓｔｉｎｅ， ｂｏｒｔｅｚｏｍｉｂ， ａｎｄ ｒｉｔｕｘｉｍａｂ ｆｏｒ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｒｅｌａｐｓｅｄ／ｒｅｆｒａｃｔｏｒｙ ｉｎｄ' Ｂｌｏｏｄ １１７（１０）, 20110310, ２８０７-２８１２
JPN6016004583; Ｇｅｒｅｃｉｔａｎｏ Ｊ ｅｔ ａｌ．: 'Ｐｈａｓｅ Ｉ ｔｒｉａｌ ｏｆ ｗｅｅｋｌｙ ａｎｄ ｔｗｉｃｅ-ｗｅｅｋｌｙ ｂｏｒｔｅｚｏｍｉｂ ｗｉｔｈ ｒｉｔｕｘｉｍａｂ， ｃｙｃｌｏｐｈｏｓｐｈａｍｉｄｅ， ａｎｄ ｐｒｅｄｎｉｓｏｎｅ' Ｃｌｉｎ Ｃａｎｃｅｒ Ｒｅｓ １７（８）, 20110415, ２４９３-２５０１
JPN5014009659; ＣＨＲＩＳＴＩＡＮ ＳＴＥＩＤＬ ｅｔ ａｌ．: 'Ｔｕｍｏｒ-Ａｓｓｏｃｉａｔｅｄ Ｍａｃｒｏｐｈａｇｅｓ ａｎｄ Ｓｕｒｖｉｖａｌ ｉｎ Ｃｌａｓｓｉｃ Ｈｏｄｇｋｉｎ'ｓ Ｌｙｍｐｈｏｍａ' ＮＥＷ ＥＮＧＬＡＮＤ ＪＯＵＲＮＡＬ ＯＦ ＭＥＤＩＣＩＮＥ Ｖｏｌ．３６２，Ｎｏ．１０, 20100311, Ｐ．８７５-８８５
JPN5014009666; Ｌｉ Ｄｉｎｇ ｅｔ ａｌ．: 'Ｂｏｒｔｅｚｏｍｉｂ ｉｎ ｃｏｍｂｉｎａｔｉｏｎ ｗｉｔｈ ＩＧＥＶ ｃｈｅｍｏｔｈｅｒａｐｙ ｒｅｇｉｍｅｎ ｆｏｒ ａ ｐｒｉｍａｒｙ ｒｅｆｒａｃｔｏｒｙ Ｈｏｄｇｋｉｎ'ｓ ｌｙｍｐｈｏｍａ' ＬＥＵＫＥＭＩＡ ＲＥＳＥＡＲＣＨ Ｖｏｌ．３３，Ｎｏ．９, 20090901, Ｐ．ｅ１７０-ｅ１７２
JPN5014009666; Ｌｉ Ｄｉｎｇ ｅｔ ａｌ．: 'Ｂｏｒｔｅｚｏｍｉｂ ｉｎ ｃｏｍｂｉｎａｔｉｏｎ ｗｉｔｈ ＩＧＥＶ ｃｈｅｍｏｔｈｅｒａｐｙ ｒｅｇｉｍｅｎ ｆｏｒ ａ ｐｒｉｍａｒｙ ｒｅｆｒａｃｔｏｒｙ Ｈｏｄｇｋｉｎ'ｓ ｌｙｍｐｈｏｍａ' ＬＥＵＫＥＭＩＡ ＲＥＳＥＡＲＣＨ Ｖｏｌ．３３，Ｎｏ．９, 20090901, Ｐ．ｅ１７０-ｅ１７２
JPN5014009658; ＭＩＮＮＡ ＴＡＳＫＩＮＥＮ: ＣＬＩＮＩＣＡＬ ＣＡＮＣＥＲ ＲＥＳＥＡＲＣＨ Ｖ１３ Ｎ１９, 20071001, Ｐ５７８４-５７８９
JPN5014009662; ＤＡＮＩＥＬＬＥ ＣＡＮＩＯＮＩ: ＪＯＵＲＮＡＬ ＯＦ ＣＬＩＮＩＣＡＬ ＯＮＣＯＬＯＧＹ Ｖ２６ Ｎ３, 20080120, Ｐ４４０-４４６
JPN6016004582; Ｆｒｉｅｄｂｅｒｇ ＪＷ ｅｔ ａｌ．: 'Ｔｈｅ ｃｏｍｂｉｎａｔｉｏｎ ｏｆ ｂｅｎｄａｍｕｓｔｉｎｅ， ｂｏｒｔｅｚｏｍｉｂ， ａｎｄ ｒｉｔｕｘｉｍａｂ ｆｏｒ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｒｅｌａｐｓｅｄ／ｒｅｆｒａｃｔｏｒｙ ｉｎｄ' Ｂｌｏｏｄ １１７（１０）, 20110310, ２８０７-２８１２
JPN6016004583; Ｇｅｒｅｃｉｔａｎｏ Ｊ ｅｔ ａｌ．: 'Ｐｈａｓｅ Ｉ ｔｒｉａｌ ｏｆ ｗｅｅｋｌｙ ａｎｄ ｔｗｉｃｅ-ｗｅｅｋｌｙ ｂｏｒｔｅｚｏｍｉｂ ｗｉｔｈ ｒｉｔｕｘｉｍａｂ， ｃｙｃｌｏｐｈｏｓｐｈａｍｉｄｅ， ａｎｄ ｐｒｅｄｎｉｓｏｎｅ' Ｃｌｉｎ Ｃａｎｃｅｒ Ｒｅｓ １７（８）, 20110415, ２４９３-２５０１
JPN5014009659; ＣＨＲＩＳＴＩＡＮ ＳＴＥＩＤＬ ｅｔ ａｌ．: 'Ｔｕｍｏｒ-Ａｓｓｏｃｉａｔｅｄ Ｍａｃｒｏｐｈａｇｅｓ ａｎｄ Ｓｕｒｖｉｖａｌ ｉｎ Ｃｌａｓｓｉｃ Ｈｏｄｇｋｉｎ'ｓ Ｌｙｍｐｈｏｍａ' ＮＥＷ ＥＮＧＬＡＮＤ ＪＯＵＲＮＡＬ ＯＦ ＭＥＤＩＣＩＮＥ Ｖｏｌ．３６２，Ｎｏ．１０, 20100311, Ｐ．８７５-８８５
JPN5014009666; Ｌｉ Ｄｉｎｇ ｅｔ ａｌ．: 'Ｂｏｒｔｅｚｏｍｉｂ ｉｎ ｃｏｍｂｉｎａｔｉｏｎ ｗｉｔｈ ＩＧＥＶ ｃｈｅｍｏｔｈｅｒａｐｙ ｒｅｇｉｍｅｎ ｆｏｒ ａ ｐｒｉｍａｒｙ ｒｅｆｒａｃｔｏｒｙ Ｈｏｄｇｋｉｎ'ｓ ｌｙｍｐｈｏｍａ' ＬＥＵＫＥＭＩＡ ＲＥＳＥＡＲＣＨ Ｖｏｌ．３３，Ｎｏ．９, 20090901, Ｐ．ｅ１７０-ｅ１７２
Attorney, Agent or Firm:
Kobayashi 浩
Kobayashi Junko
Norio Omori
Yasuhito Suzuki
Kobayashi Junko
Norio Omori
Yasuhito Suzuki